Two liver treatments followed by immunotherapy for eye melanoma

Plain-English translation of NCT07276386 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial combines two approaches to fight uveal melanoma (a type of eye cancer) that has spread to the liver. First, you receive two specialized procedures called percutaneous hepatic perfusion (PHP) that deliver chemotherapy directly to liver tumors while protecting the rest of your body. Then, starting a few weeks later, you receive weekly injections of , an immunotherapy drug that helps your immune system recognize and attack cancer cells. The researchers believe that the liver procedures may help make the cancer cells more vulnerable to the immunotherapy.

Uveal melanoma that spreads to the liver is very difficult to treat and has few good options. This trial is testing whether combining a liver-targeted chemotherapy procedure with immunotherapy might work better than either treatment alone, especially for patients whose immune system can respond to .

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with eye melanoma that has spread to your liver
you have a specific genetic marker called HLA-A*02:01 (a blood test can check this)
you are in good enough overall health to undergo anesthesia and these procedures
you have measurable tumors in your liver that can be seen on CT scans

You likely don't qualify if…

you have heart disease, severe lung disease, or conditions that prevent you from having general anesthesia
you have kidney disease or severe liver damage beyond what the cancer has caused
you have more than half of your liver replaced by tumors
you have widespread cancer outside the liver that cannot be treated before starting the study
you are pregnant or plan to become pregnant during the study and for 5 months after

What participation looks like

You would have two liver procedures about 6–8 weeks apart, each requiring anesthesia and a brief hospital stay. After your second procedure, you would start weekly injections of the immunotherapy medication, which you would receive for one year. During this year, you would have regular clinic visits and imaging scans to check how well the treatment is working. If your cancer continues to grow while on the medication, you may be offered additional liver procedures as part of your standard care.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(1 site)

United States

Moffitt Cancer Center, Tampa, Florida